# Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

> **NCT00091273** · PHASE1 · COMPLETED · sponsor: **University of Virginia** · enrollment: 9 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** ovarian cancer peptide vaccine
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** tetanus toxoid helper peptide
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00091273
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-02
- **Final completion:** 2007-06
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2014-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091273, "Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00091273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*